Core Laboratories Inc DE
For the period ended Sep 30, 2024. Filed Oct 24, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Oct 24, 2024
CLB$9.03+2.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets at September 30, 2024 (Unaudited) and December 31, 2023
CONSOLIDATED BALANCE SHEETS
| September 30,2024 | December 31,2023 | |
|---|---|---|
| (Unaudited) | ||
| ASSETS | ||
| CURRENT ASSETS: | ||
| Cash and cash equivalents | $21,474 | $15,120 |
| Accounts receivable, net of allowance for credit losses of $3,152 and $2,280 at 2024 and 2023, respectively | 117,591 | 109,352 |
| Inventories | 65,490 | 71,702 |
| Prepaid expenses | 9,717 | 8,153 |
| Income taxes receivable | 14,784 | 13,716 |
| Other current assets | 6,171 | 5,093 |
| TOTAL CURRENT ASSETS | 235,227 | 223,136 |
| PROPERTY, PLANT AND EQUIPMENT, net of accumulated depreciation of $318,871 and $315,796 at 2024 and 2023, respectively | 97,606 | 99,626 |
| RIGHT OF USE ASSETS | 56,650 | 53,842 |
| INTANGIBLES, net of accumulated amortization and impairment of $19,204 and $18,825 at 2024 and 2023, respectively | 6,547 | 6,926 |
| GOODWILL | 99,445 | 99,445 |
| DEFERRED TAX ASSETS, net | 69,948 | 69,201 |
| OTHER ASSETS | 35,043 | 34,219 |
| TOTAL ASSETS | $600,466 | $586,395 |
| LIABILITIES AND EQUITY | ||
| CURRENT LIABILITIES: | ||
| Accounts payable | $33,627 | $33,506 |
| Accrued payroll and related costs | 22,281 | 18,791 |
| Taxes other than payroll and income | 5,795 | 5,939 |
| Unearned revenues | 7,208 | 4,755 |
| Operating lease liabilities | 11,435 | 10,175 |
| Income taxes payable | 5,459 | 7,280 |
| Other current liabilities | 9,133 | 7,651 |
| TOTAL CURRENT LIABILITIES | 94,938 | 88,097 |
| LONG-TERM DEBT, net | 139,872 | 163,134 |
| LONG-TERM OPERATING LEASE LIABILITIES | 43,727 | 42,076 |
| DEFERRED COMPENSATION | 31,713 | 30,544 |
| DEFERRED TAX LIABILITIES, net | 13,547 | 12,697 |
| OTHER LONG-TERM LIABILITIES | 20,248 | 20,040 |
| COMMITMENTS AND CONTINGENCIES | ||
| EQUITY: | ||
| Preference stock, 6,000,000 shares authorized, $0.01 par value; none issued or outstanding | — | — |
| Common stock, 200,000,000 shares authorized, $0.01 par value, 46,938,557 issued and 46,927,391 outstanding at 2024; 46,938,557 issued and 46,856,536 outstanding at 2023 | 469 | 469 |
| Additional paid-in capital | 112,610 | 110,011 |
| Retained earnings | 143,346 | 120,756 |
| Accumulated other comprehensive income (loss) | (5,446) | (4,972) |
| Treasury stock (at cost), 11,166 and 82,021 shares at 2024 and 2023, respectively | (237) | (1,449) |
| Total Core Laboratories Inc. shareholders' equity | 250,742 | 224,815 |
| Non-controlling interest | 5,679 | 4,992 |
| TOTAL EQUITY | 256,421 | 229,807 |
| TOTAL LIABILITIES AND EQUITY | $600,466 | $586,395 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.